[Incidence of antinuclear antibodies during treatment with acebutolol. A 1-year prospective study in 45 hypertensive patients treated by monotherapy].
Determinations of antinuclear antibodies (ANA) were performed before treatment, then every 3 months for one year, in 45 hypertensive patients treated with acebutolol alone in daily doses equal or superior to 800 mg. Non significant ANA titers (1/10 to 1/40) were detected before treatment in 8.8% of the patients. After one year of treatment, 15.5% of the patients were found to have antinuclear antibodies. In 4 (8.8%) female patients (3 of whom were ANA-negative before treatment) the ANA titers were above 1/40. Treatment was discontinued in one of these due to the occurrence of bronchospasm. No lupus-like syndrome was observed during the course of the study. Prolonged prospective studies with acebutolol alone would be required to determine whether in the long term the incidence of significant ANA titers remains at the 8.8% level or increases.
D000070:Acebutolol / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors
D000974:Antibodies, Antinuclear; D000070:Acebutolol
Incidence des anticorps antinucléaires au cours des traitements par acébutolol. Etude prospective sur 1 an chez 45 hypertendus traités en monothérapie.